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Abstract
Objective—The Georgia Lupus Registry is a population-based registry designed to improve our 
ability to estimate incidence and prevalence of systemic lupus erythematosus (SLE) in a large 
population.
Methods—Potential cases were identified from multiple sources during the years 2002 through 
2004. Cases were defined by the American College of Rheumatology (ACR) Criteria for SLE or a 
combined definition. Age-standardized rates were determined and stratified by race and sex. With 
capture-recapture analyses, we estimated the under-ascertainment of cases.
Results—Using the ACR case definition, the overall crude and age-adjusted incidence rate was 
5.6/100,000, with capture-recapture and combined definition rates being slightly higher. The age-
adjusted incidence rate for women was >5 times higher (9.2 vs. 1.8) than that for men. Black 
women had an incidence rate nearly 3 times higher than that for white women with a significantly 
higher rate in the 30 to 59 years age group. The overall crude and age-adjusted prevalence rates 
were 74.4 and 73/100,000, respectively. The age-adjusted prevalence rate for women was nearly 9 
times higher (127.6 vs. 14.7) than that for men. Black women had very high rates (196.2). A 
striking difference was seen in the proportion with end-stage renal disease in prevalent cases, with 
a sevenfold greater involvement among blacks.
Conclusion—With more complete case finding, our incidence and prevalence rates are among 
the highest reported in the United States. Results continue to underscore striking gender, age, and 
racial disparities between blacks and whites.
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In the 1950’s, systemic lupus erythematosus (SLE) was thought to be rare, predominantly 
afflicting females with light hair, fair skin, and “inability to tan” (1). An epidemiologic study 
from 1956–65 showed for the first time the higher burden of disease in black women 
compared to their white counterparts (2). We now appreciate the disproportionate burden of 
SLE on women, particularly in their childbearing years, and in certain racial groups. These 
epidemiologic studies advanced our understanding of the burden of SLE but were limited in 
their ability to find all cases in the population and thus describe the full spectrum of 
diagnosed SLE.
Given the recent significant increase in awareness of and research in SLE, along with the 
availability of innovative techniques (3), the purpose of this Georgia Lupus Registry (GLR) 
study is to advance our epidemiologic understanding of SLE by doing more complete case 
finding in a targeted population, avoiding referral bias in a particular institution, using 
available case definitions to better define the incidence and prevalence of diagnosed SLE, 
and characterizing individuals with this disease from a population perspective. The GLR is 
one of two recently completed Centers for Disease Control and Prevention (CDC) funded 
population-based lupus registries designed to minimize many of the limitations of previous 
studies. An innovative tool in this approach is the use of the state public health surveillance 
exemption to the Health Insurance Portability and Accountability Act (HIPAA) to acquire 
greater access to protected health information without requiring individual patient consent, a 
limitation that can bias findings. This novel and powerful approach allows for an 
unprecedented completeness of case finding from multiple sites of ascertainment throughout 
the targeted community. Coupled with detailed training of abstractors, strict quality control 
of data gathering and processing, multiple sources of case ascertainment that minimizes bias 
from a consent process or institution type, and the high number of cases, this study provides 
more reliable population-based estimates of incidence and prevalence of SLE than 
previously reported.
Patients and Methods
THE GEORGIA LUPUS REGISTRY
In 2002, the CDC Arthritis Program funded the Georgia Department of Public Health (GA 
DPH) to conduct surveillance of SLE in 2 Georgia counties with large black populations 
(Fulton and DeKalb) (3). To avoid biased ascertainment and underreporting as a result of 
recruiting large numbers of community patients, the GA DPH, as a “public health 
authority”, used its public health surveillance exemption to the HIPAA Privacy Rule (45 
CFR parts 160 and 164) to obtain protected health information (PHI) without written patient 
consent (45 CFR 164.512[b]). PHI was needed to determine if diagnosed cases met the 
various case definition criteria and to provide enough information to prevent duplicate 
counting of patients when the same patient was encountered in multiple facilities. The GA 
DPH contracted with Emory University as its designated agent to provide lupus expertise 
and manage the project. CDC considered this surveillance project to be “public health 
practice” (rather than research) that did not need CDC Institutional Review Board (IRB) 
review, but it was reviewed and approved by the IRB’s at Emory University and the GA 
DPH.
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STUDY POPULATION AND PERIOD
The study population consisted of residents of Fulton and DeKalb counties, which include 
the city of Atlanta. Prevalence was estimated for 2002 and incidence for 2002–2004. The 
Bureau of the Census estimate in 2002 for the two counties was 1,552,970 with 51.1% 
women, 49.3% blacks, and 46.4% whites (4) and remained stable in 2003–04. The registry 
captured diagnosed cases retrospectively. Case ascertainment efforts began in late 2004 in 
order for data elements to have had time to be captured in various records and data systems. 
Given the tremendous effort required to obtain and validate cases through multiple sources 
in the pluralistic US health care system, data collection was not completed until 2011.
CASE DEFINITIONS
SLE is a complex disease that is currently defined using a variety of case definitions. The 
gold standard case definition is diagnosis by expert clinical assessment, usually a 
rheumatologist, which is impractical for large population-based studies. We used 3 case 
definitions for this study:
1. ≥ 4 ACR criteria. The most widely accepted standard is meeting ≥4 of 11 criteria in 
the 1997 update of the 1982 American College of Rheumatology (ACR) Revised 
Classification Criteria for SLE (≥ 4 ACR criteria) (5, 6).
2. Treating rheumatologist’s diagnosis. Those with 3 ACR criteria were required to 
have a documented statement of diagnosis of SLE in the medical record by a board-
certified rheumatologist. This acknowledges that a clinical diagnosis by the treating 
rheumatologist with direct access to the patient is important, particularly in 
prevalent patients with longstanding disease where certain records may have been 
inaccessible or lost over time for our study.
3. <4 ACR criteria plus lupus kidney disease. In the absence of fulfilling ≥4 of 11 
ACR criteria, those with SLE renal involvement were defined by either:
a. a biopsy consistent with class II–VI lupus nephritis (7–9). These biopsies 
were linked to SLE administrative coding or clinical documentation and 
were deemed significant enough of a clinicopathologic finding to suggest a 
case has SLE in the absence of meeting full ACR criteria (10).
b. end-stage renal disease (ESRD) requiring dialysis or renal transplantation 
with documentation of SLE in the medical record. This avoids missing 
patients who may have spent most of their time at dialysis centers for care 
and/or were busy dealing with other comorbidities. The likelihood of being 
able to locate or access medical records where most ACR criteria are 
documented decreases for these patients. Incident and prevalent patients may 
have achieved ESRD status before 2004 or 2002, respectively.
For analytic purposes, we report results in two ways: for the standard case definition (≥ 4 
ACR Criteria) alone and for a “combined” case definition that includes all 3 case definitions.
Incident cases were defined as those newly diagnosed with SLE from January 1, 2002 
though December 31, 2004 and prevalent cases were defined as those with a diagnosis of 
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SLE of any duration during the year 2002. Both must also have met a case definition with a 
documented address in one of the two targeted counties during the time of interest.
CASE ASCERTAINMENT, SCREENING, AND VALIDATION
The primary sources of potential cases included hospitals, rheumatologists, nephrology 
groups, and dermatology groups in and around the catchment area (Figure 1). 
Administrative databases were queried retrospectively for the International Classification of 
Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnostic code 710.0 (SLE), 
as well as 695.4 (discoid lupus), 710.8 (other specified connective tissue disease), and 710.9 
(unspecified connective tissue disease). Antiphospholipid antibody syndrome, which lacks a 
specific ICD-9-CM code, was searched for if a consistent code was utilized at a particular 
facility.
Secondary sources included regional commercial and hospital-based laboratories, which 
were queried respectively for anti-nuclear antibodies (ANA) titer ≥ 1:320, anti-DNA and/or 
anti-Sm antibodies, depressed complement levels, and anti-cardiolipin antibodies. Pathology 
laboratories were queried for cutaneous and renal biopsies consistent with lupus. Data were 
also obtained from the Veterans Administration, electronic medical record systems, and the 
US Renal Data System (USRDS), which captures all patients with end stage renal disease 
receiving any kidney replacement therapy (e.g., dialysis or kidney transplantation).
After final screening for residency in the target counties during the target time period, 
available medical records were abstracted for over 200 data elements, each with detailed 
definitions in a data dictionary; elements were sought continuously from all sources (without 
stopping when a certain number of case definition criteria were met). Demographic 
information, such as race, was obtained from the medical record. Date of diagnosis was the 
earliest date assigned in the medical record by the patient’s treating physician because the 
date at which the patient met ≥4 ACR criteria, often used to define incidence in prospective 
studies, was difficult to accurately ascertain retrospectively.
Abstractors were thoroughly trained and tested by board-certified rheumatologists who were 
expert in lupus before entering the field, where they continued to undergo quality 
assessments every 100 records. This required a minimum inter-observer agreement of 90% 
of all elements and 95% of ACR criteria using the Principal Investigators’ (SL, CD) 
abstraction as the gold standard or remedial training until those criteria were met.
STATISTICAL ANALYSIS
Crude SLE incidence rates and 95% confidence intervals as well as race- and sex-stratified 
rates were estimated using methods based on the Poisson distribution (11). Denominator 
data for estimating rates for DeKalb and Fulton counties for the years 2002–2004 were 
obtained from the postcensal population estimates (4). Age-adjusted estimates and 95% 
confidence intervals were calculated based on the standard 2000 projected age distribution 
by the direct method using R (routine ageadjust.direct) (12), which calculates age 
standardized (adjusted) rates and “exact” confidence intervals based on the gamma 
distribution (13). Similar methods were used to estimate 2002 prevalence.
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Capture-recapture (C-RC) methods estimate the completeness of case ascertainment when 
using multiple information sources. Log-linear models were used to estimate the true SLE 
population size by evaluating the degree of overlap among three data sources – hospitals, 
specialists, and health care systems, which were chosen by expert opinion from the 
investigators (SL, CD) to be the primary sources of cases. Modeling was performed 
separately for incident and prevalent data based on those patients who met the case 
definition of ≥ 4 ACR Criteria. The log-linear model was used to estimate the number of 
persons who were missed in the population.
Seven hierarchical log-linear models were fit to the data (one model assuming independence 
among the three data sources; three models of pairwise interaction; and three models of two 
pairwise interactions). The best fitting model was determined by goodness of fit statistics 
and the parsimony principle. Based on the estimated undercount, revised (C-RC) estimates 
of incidence and prevalence were calculated. All (C-RC) analyses followed the methods 
described by Bishop et al and McCarty et al and were implemented using SAS Proc Genmod 
(14, 15).
Results
INCIDENCE - ≥ 4 ACR CRITERIA
In 2002–2004, 267 cases fulfilled ≥ 4 ACR criteria for SLE, including 196 blacks, 62 
whites, and 9 other races (Table 1). The overall crude and age-adjusted incidence rates were 
similar [5.6 per 100,000 person-years]. Age-adjusted incidence rates were 5 times higher 
among women than men [9.2 (95% CI, 8.1–10.5) vs. 1.8 (95% CI, 1.3–2.4)]. Among 
women, age-adjusted rates for blacks were nearly 3 times higher than that for whites (13.4 
vs. 4.7); among men, rates for blacks were >4 times higher than that for whites (3.2 vs. 0.7). 
C-RC analysis estimated 31 (95% CI, 18–55) missed SLE cases resulting in a higher C-RC 
adjusted rate of 6.3 per 100,000 person-years.
Overall age-specific rates were significantly different between blacks and whites in both 
women and men. Figure 2 shows age-specific rates by sex and race. Black women had 
significantly higher IR’s compared to white women in the 30–59 age range, especially in the 
30–39 age strata (Figure 2A). Age-specific differences were not found between blacks and 
whites in men, though there were significantly fewer numbers of men in these strata (Figure 
2B).
The overall average age at diagnosis was 40.5 (s.d.±16.5) years, with no significant 
difference between women and men (40.7±16.3 vs. 39.4±17.9 years, p=0.48). However, 
blacks were significantly younger at diagnosis compared with whites (39.4±15.9 vs. 
45.4±17.7 years, p=0.016). Among women, the only incident cases in those <12 years of age 
were blacks. In the 12–19 age strata, black women and men predominated, with white cases 
only coming from women.
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INCIDENCE – COMBINED CASE DEFINITION
The “combined” case definition yielded an additional 78 cases and a total of 345 incident 
cases, increasing the crude and adjusted rates to 7.3 and 6.9 per 100,000 person-years, 
respectively (Table 1). Of these 78 cases, 72 met 3 ACR criteria, 13 had a renal biopsy 
consistent with lupus nephritis (5 of these had a documented anti-nuclear antibody (ANA) 
and/or anti-DNA antibody), and none had ESRD. All patients were identified as black or 
white except for 11 Asians and 3 with unknown race.
Using the “combined” case definition, the age-adjusted rate for women was 6 times higher 
than that for men (11.7 vs. 1.9 per 100,000 person-years). The age-adjusted rate for blacks 
was 3.2 times higher than that for whites (10.7 vs. 3.3 per 100,000 person-years). The 
proportions were different when comparing gender by race. The rate in women was 2.9 
times higher in blacks than whites (17.0 vs. 5.8 per 100,000 person-years). Black men had a 
4.3 times greater rate compared with white men (3.4 vs. 0.8 per 100,000 person-years).
PREVALENCE - ≥ 4 ACR CRITERIA
In 2002, 1,156 cases fulfilled ≥ 4 ACR criteria for SLE, including 889 blacks, 251 whites, 
and 16 other races (Table 2). The overall crude prevalence rate (PR) was 74.4 (95% CI, 
70.3–78.9) per 100,000 person-years. Age-adjusted PRs were similar to the crude rates. The 
age-adjusted PR for women was nearly 9 times higher than that for men (127.6 vs. 14.7). 
Among women, the PR for blacks was >3 times higher than that for whites (196.2 vs. 59); 
among men, the PR for blacks was >3 times higher than that for whites (23.7 vs. 7.5). C-RC 
analysis was done only for the ≥4 ACR criteria case definition and estimated 133 (95% CI, 
98–181) missing SLE cases resulting in a C-RC adjusted PR of 83 per 100,000 person-years.
PREVALENCE – COMBINED CASE DEFINITION
The “combined” case definition yielded an additional 290 cases for a total of 1,446 prevalent 
cases, increasing the crude and adjusted PRs to 93.1 and 92.1 per 100,000 person-years, 
respectively (Table 2). Of these 290 cases, 213 met 3 ACR criteria, 52 had a renal biopsy 
consistent with lupus nephritis (27 of these had a documented ANA and/or anti-DNA 
antibody), and 49 had ESRD. Of those with ESRD, 11 had a documented ANA and/or anti-
DNA antibody and all had less than 3 ACR criteria (8 had a documented ANA and/or anti-
DNA antibody).
The age-adjusted PR for women was >8 times higher than that for men (159.8 vs. 19.6). The 
age-adjusted PR for blacks was >3 times higher than that for whites, 147.5 vs. 43.1 per 
100,000 person-years. When comparing the age-adjusted PRs in women, blacks were >3 
times higher than whites (241.5 vs. 77.7); in men, blacks were >3 times higher than whites 
(32.2 vs. 9.6). Overall rates were significantly different between blacks and whites in both 
women and men. Black women had significantly higher PRs compared to white women 
across all age strata except for ages 0–11 and ≥ 70 (Figure 2C). For men, PRs were 
noticeably higher in blacks compared to whites between ages 20 and 49 (Figure 2D).
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Among incident cases with ≥4 ACR criteria, arthritis, hematologic, and serologic ACR 
Criteria were the most common through the first year after the diagnosis (Table 3). The next 
most frequent were renal disorder and serositis in blacks, and photosensitivity and oral 
ulcers in whites. Less than 2% of incident cases had documented ESRD through the first 
year after the diagnosis. However, among prevalent cases, the proportion of blacks with 
ESRD was 8.4% and whites 1.2%.
Discussion
SLE is one of the most challenging conditions to study on a population level. Several studies 
throughout the world have attempted to advance our epidemiologic knowledge of SLE and 
results have varied widely. We have limited our review in this manuscript to those in the 
North American region (Table 4). Discrepancies in rates are in part due to the inherent 
disparities of SLE (i.e., higher rates in certain ethnic groups). Other reasons include the use 
of different case definitions, biased sources for case ascertainment, small source 
populations, the different demographic groups targeted, the protean manifestations of the 
disease that make diagnosis difficult, the poor reliability of self-report, the lack of reliability 
in coding in health system databases, and poor access to health care for high-risk 
populations. These latter differences not only exist across different countries and health care 
systems, but also within the same country. Although no one study can address these 
limitations completely, the methodologic advances in this study resulted in some of the most 
reliable population-based estimates of incidence and prevalence of SLE.
Leveraging the state’s public health surveillance exemption to obtain and review patient 
information from medical records and various databases without consent was a powerful 
tool to maximize case ascertainment that had never been utilized before for SLE. This led to 
a better population-based assessment without compromising patient confidentiality. This 
also required significant effort in maximizing the quality of the data, which was enhanced 
through the collection of uniformly defined data elements, regular quality assessments of the 
abstractors and data, and sharing of best practices with a parallel registry in Michigan 
through monthly teleconferences facilitated by the CDC. Multiple sources of cases captured 
a wide spectrum of disease, both phenotypically and the degree of disease severity. This 
included all major sources of pediatric cases. The large numbers of cases led to greater 
precision of the estimates and power to compare certain groups.
How cases are defined is essential to a study’s interpretation and comparability to other 
studies. The “gold standard” for diagnosing SLE is by clinical assessment from an 
experienced clinician (i.e., a rheumatologist), which is often impractical for population-
based studies. Currently, the most commonly accepted definition is the updated 1997 ACR 
Criteria for the Classification of SLE (5, 6). While the use of ACR criteria enhances the 
comparability of research studies, the sensitivity of the 1982 criteria has been shown to be 
only 83% in an external population versus 96% in the test population. The criteria also tend 
to be skewed towards limited detection of mild cases of SLE and incident cases at early 
stages of their prodrome. The population size would, therefore, be underestimated and 
biased towards those of longer disease duration and greater severity. Epidemiologic studies 
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would benefit from alternative definitions for comparison. Since the fulfillment of a single 
case definition in the field did not limit the extent of information that was obtained, this 
study utilized an alternative definition that improved sensitivity while minimizing impact to 
specificity, which is acceptable for a large epidemiologic study. Previous studies often 
utilized one definition. Alternative definitions, if available, were often those who met 
incomplete ACR criteria. Diagnoses validated with administrative data or by self-report 
have limitations and should be supplemented with additional data in situations when medical 
review is not feasible (16, 17).
The burden of SLE in the Atlanta, Georgia area is significant, with an overall age-adjusted 
prevalence rate among the highest reported in the US at 73 per 100,000 person-years by 
ACR Criteria, 83 by C-RC, and 92.1 by combined case definition. The overall age-adjusted 
incidence rate is similarly high at 5.6 per 100,000 person-years by ACR Criteria, 6.3 by C-
RC, and 6.9 by combined case definition. Use of the combined case definition yielded 
higher rates and underscores some limitations of the ACR Classification Criteria, which 
should be viewed as a minimal estimate in this retrospective study given the potential for 
data to be missed or overlooked (18). High rates may, in part, be due to improved awareness 
of SLE leading to increased referrals and testing, as well as improved 5-year survival rates 
that have gone from <50% to >90% due to earlier diagnosis and more aggressive treatment 
(19, 20). Including undiagnosed or early cases, which were not addressed in this study, 
would raise these estimates.
Striking gender, age, and racial disparities in SLE have been confirmed. Women have an 
age-adjusted incidence rate >5 times higher and prevalence rate >8 times higher than men 
using the ACR Criteria. The relatively higher female to male ratio that we found in prevalent 
(8:1) compared to incidence cases (5:1) may be related to a greater awareness among 
physicians of SLE in general and as a result in men. Likewise, mortality has been reported to 
be relatively higher in men than in women, particularly by studies from the 1980’s and 
1990’s (21). As the diagnosis and life expectancy of SLE improves, further mortality studies 
will advance our understanding of potential differences in the burden of disease and its 
outcomes by sex. Blacks have an incidence and prevalence rate >3 times higher and develop 
SLE earlier than whites. SLE particularly burdens black women, with some of the highest 
incidence and prevalence rates ever reported (15, 22). Black women between the ages of 30–
59 are at particularly high risk for developing SLE (Figure 2A). In women <20 years old, 
there were only 4 incident cases in whites as compared to 20 in blacks. Only black women 
developed SLE in ages <12 (n=5). Although age-specific prevalence rates were significantly 
higher for black women compared to their white counterparts across all age groups, the 
difference was more striking between the ages of 30 and 69 (Figure 2C). In men, blacks also 
had higher prevalence rates compared to whites, particularly between ages 20 and 50 (Figure 
2D). Our findings suggest that different age-related patterns of mortality by sex and race 
may occur in SLE patients as indicated in prior studies (23).
The burden of ESRD continues to be high, afflicting 6.7% and 1.9% of prevalent and 
incident cases (≥ 4 ACR criteria), respectively. A striking difference was seen in the 
proportion with ESRD, where there was no racial difference among incident cases but a 7 
fold greater involvement among blacks among prevalent cases. Some of this can be 
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explained by an inherently higher risk in those of African descent to develop nephritis (24). 
However, it also indicates a strong potential for disparities in health care access and other 
socioeconomic factors (25). 49 out of 127 prevalent ESRD cases did not have at least 3 ACR 
criteria indicating that up to a third of ESRD cases from lupus nephritis may not meet ACR 
criteria. A consistent renal biopsy, particularly in the setting of suggestive autoantibodies, is 
felt to be indisputable evidence for SLE and should be considered as sufficient “stand alone” 
clinical criteria in prospective studies (26). In an epidemiologic study such as this, given that 
SLE patients with ESRD are seen less often by rheumatologists and nephrologists outside 
dialysis centers, documentation of many of these serologies may have been lost with 
archived or destroyed records.
There are several limitations to this study. First, the US healthcare system is complex, 
heterogeneous, and fragmented, requiring that each practice and institution be approached 
separately to voluntarily participate in this study. Second, data were collected retrospectively 
from medical records designed for clinical use and varied tremendously with respect to 
organization, legibility, and accessibility. The result of these 2 limitations was a labor-
intensive process that required work into 2011 to evaluate the study period of 2002–04. 
Although trained abstractors were audited periodically to ensure consistency and accuracy, a 
degree of variability of clinical diagnosis by rheumatologists cannot be excluded. As a result 
of the retrospective nature of this registry, the degree in which the experience of treating 
physicians impacting the definition of cases, particularly of those with milder disease or 
fewer number of ACR criteria, cannot be determined. Third, there is underascertainment of 
serologic tests, particularly in prevalent cases in which diagnostic tests could have occurred 
many years ago and the results lost in the records, thus leading to lower rates of documented 
ANA and other autoantibodies than what would have been expected in a prospective study 
(table 3). Fourth, the catchment area was defined by artificial county boundaries. Fifth, the 
results of this study are best generalized to whites and blacks in the Southeastern US and not 
to other racial/ethnic groups and in other regions or countries. Sixth, race/ethnicity was 
assigned based primarily on the physician assessment as documented in the medical record. 
This may not reflect the patient’s true self-identity. Finally, this study was not able to 
estimate the rate of undiagnosed disease.
The GLR advances our epidemiologic understanding of SLE, a complicated and difficult to 
diagnose disease, and confirms the significant burden of SLE, particularly in younger black 
women and ESRD in blacks compared to whites. It is part of a larger, coordinated effort to 
more accurately estimate the burden of SLE among other high-risk groups in the US, such as 
Hispanics, Asians, and American Indians/Alaska Natives. Experience from this study could 
also inform efforts to develop ongoing surveillance of SLE and other medical conditions for 
which similar challenges exist.
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